Share Price and Basic Stock Data
Last Updated: January 8, 2026, 6:39 am
| PEG Ratio | 0.37 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bliss GVS Pharma Ltd operates within the pharmaceuticals industry and has reported a current market capitalization of ₹1,990 Cr and a share price of ₹187. The company’s revenue from operations has shown notable fluctuations over the past quarters, with sales rising from ₹172 Cr in September 2022 to ₹212 Cr in September 2023. For the fiscal year ending March 2025, sales are projected to reach ₹810 Cr, an increase from ₹752 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue stands at ₹860 Cr, indicating a positive growth trajectory. The operating profit margin (OPM) has varied, currently standing at 13%, with the highest recorded at 26% in September 2023. This revenue growth reflects Bliss GVS’s strategic positioning within the competitive pharmaceutical landscape, although the company faces challenges in maintaining consistent profitability amidst fluctuating operational costs.
Profitability and Efficiency Metrics
Bliss GVS Pharma has reported a net profit of ₹115 Cr, translating to a P/E ratio of 18.2. The company’s return on equity (ROE) stands at 8.36%, while return on capital employed (ROCE) is reported at 11.7%, indicating moderate returns on investments made. The operating profit has fluctuated, with the highest recorded at ₹54 Cr in September 2023, while the lowest was just ₹6 Cr in March 2023. The company’s interest coverage ratio is robust at 20.10x, reflecting its ability to meet interest obligations comfortably. However, the cash conversion cycle (CCC) of 246 days indicates potential inefficiencies in working capital management, as longer cycles can strain liquidity. Overall, while Bliss GVS demonstrates reasonable profitability metrics, the volatility in operating profits and the extended CCC highlight areas that require management focus to enhance operational efficiency.
Balance Sheet Strength and Financial Ratios
Bliss GVS’s financial position appears solid, with total assets amounting to ₹1,400 Cr and total borrowings limited to ₹52 Cr. This low debt level results in a total debt to equity ratio of just 0.06, suggesting a conservative approach to financing that minimizes risk. The company has accumulated reserves of ₹1,122 Cr, enhancing its financial flexibility for future investments. The current ratio is reported at 4.81, significantly above the industry average, indicating strong short-term liquidity. However, the return on assets (ROA) at 6.48% is relatively modest compared to sector benchmarks. The price to book value (P/BV) ratio stands at 1.18x, suggesting the stock is slightly overvalued in relation to its book value, which could deter some investors seeking undervalued opportunities. Overall, Bliss GVS maintains a strong balance sheet, yet the efficiency of asset utilization remains an area for improvement.
Shareholding Pattern and Investor Confidence
The shareholding structure of Bliss GVS Pharma reflects a diverse ownership model. Promoters hold 35.39% of the company, while institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), account for 13.27% and 5.98%, respectively. The public holds a significant portion at 45.36%, indicating a broad base of retail ownership. Over recent quarters, the promoter holding has seen slight fluctuations, but it remains stable, which can signal investor confidence. The number of shareholders has also varied, currently standing at 44,461. However, the declining trend in FII participation from a high of 16.53% in December 2022 to 13.27% in September 2025 may raise concerns regarding foreign investor sentiment. This mixed ownership structure may influence market perceptions and stability, positioning the company for both opportunities and potential volatility depending on market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Bliss GVS Pharma faces a blend of opportunities and risks. The company’s growth prospects are bolstered by increasing sales and a healthy balance sheet, allowing for strategic investments in innovation and market expansion. However, the volatility in operating profits and high cash conversion cycle pose risks to sustained profitability. Additionally, regulatory changes and competitive pressures within the pharmaceutical sector could impact operational performance. The potential for improving efficiency in working capital management presents an avenue for enhancing profitability. In scenarios where the company can successfully streamline operations and maintain its revenue growth, it could significantly enhance shareholder value. Conversely, failure to address operational inefficiencies and declining foreign investment interest could limit growth potential and affect market positioning. Thus, while Bliss GVS shows promise, careful navigation of its operational challenges will be critical for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.51 Cr | 1,159.04 | 54.42 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 172 | 206 | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 |
| Expenses | 148 | 158 | 179 | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 213 |
| Operating Profit | 25 | 48 | 6 | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 32 |
| OPM % | 14% | 23% | 3% | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 13% |
| Other Income | 2 | 6 | 3 | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 20 |
| Interest | 2 | 1 | 5 | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 |
| Depreciation | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 |
| Profit before tax | 20 | 47 | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 |
| Tax % | 21% | 37% | -561% | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% |
| Net Profit | 16 | 30 | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 |
| EPS in Rs | 1.33 | 2.68 | 0.32 | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 |
Last Updated: January 2, 2026, 5:32 am
Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 244.00 Cr.. The value appears strong and on an upward trend. It has increased from 207.00 Cr. (Jun 2025) to 244.00 Cr., marking an increase of 37.00 Cr..
- For Expenses, as of Sep 2025, the value is 213.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 166.00 Cr. (Jun 2025) to 213.00 Cr., marking an increase of 47.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Jun 2025) to 32.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Jun 2025) to 13.00%, marking a decrease of 7.00%.
- For Other Income, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Jun 2025) to 20.00 Cr., marking a decrease of 15.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Jun 2025) to 41.00 Cr., marking a decrease of 22.00 Cr..
- For Tax %, as of Sep 2025, the value is 30.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 30.00%.
- For Net Profit, as of Sep 2025, the value is 29.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Jun 2025) to 29.00 Cr., marking a decrease of 15.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.58. The value appears to be declining and may need further review. It has decreased from 4.08 (Jun 2025) to 2.58, marking a decrease of 1.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 860 |
| Expenses | 273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 736 |
| Operating Profit | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 124 |
| OPM % | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 14% |
| Other Income | 28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 83 |
| Interest | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 11 |
| Depreciation | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 32 |
| Profit before tax | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 164 |
| Tax % | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | |
| Net Profit | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 115 |
| EPS in Rs | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 10.39 |
| Dividend Payout % | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 48.78% | 63.93% | 13.00% | -21.24% | 42.70% | -25.20% | -22.11% | -68.92% | 234.78% | 6.49% | 9.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.15% | -50.93% | -34.24% | 63.94% | -67.89% | 3.09% | -46.81% | 303.70% | -228.29% | 3.26% |
Bliss GVS Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -5% |
| 3 Years: | 44% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 24% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 9% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 | 1,122 |
| Borrowings | 173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 52 |
| Other Liabilities | 123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 162 | 215 |
| Total Liabilities | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,400 |
| Fixed Assets | 213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 392 |
| CWIP | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 39 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 10 |
| Other Assets | 365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 870 | 959 |
| Total Assets | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,400 |
Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,122.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,040.00 Cr. (Mar 2025) to 1,122.00 Cr., marking an increase of 82.00 Cr..
- For Borrowings, as of Sep 2025, the value is 52.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 88.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 36.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 162.00 Cr. (Mar 2025) to 215.00 Cr., marking an increase of 53.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,400.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,301.00 Cr. (Mar 2025) to 1,400.00 Cr., marking an increase of 99.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 392.00 Cr.. The value appears to be declining and may need further review. It has decreased from 406.00 Cr. (Mar 2025) to 392.00 Cr., marking a decrease of 14.00 Cr..
- For CWIP, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 10.00 Cr., marking an increase of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 959.00 Cr.. The value appears strong and on an upward trend. It has increased from 870.00 Cr. (Mar 2025) to 959.00 Cr., marking an increase of 89.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,400.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,301.00 Cr. (Mar 2025) to 1,400.00 Cr., marking an increase of 99.00 Cr..
Notably, the Reserves (1,122.00 Cr.) exceed the Borrowings (52.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -102.00 | -57.00 | 24.00 | -22.00 | 79.00 | 58.00 | -3.00 | -15.00 | 9.00 | 15.00 | 51.00 | 39.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 |
| Inventory Days | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 |
| Days Payable | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 |
| Cash Conversion Cycle | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 |
| Working Capital Days | 86 | 105 | 84 | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 199 |
| ROCE % | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 669 | 0.07 | 0.01 | 669 | 2025-04-22 17:25:40 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.02 | 7.23 | 6.83 | 1.46 | 6.64 |
| Diluted EPS (Rs.) | 7.95 | 7.11 | 6.72 | 1.43 | 6.49 |
| Cash EPS (Rs.) | 11.36 | 10.31 | 9.16 | 3.90 | 8.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Revenue From Operations / Share (Rs.) | 76.85 | 73.57 | 72.16 | 72.09 | 55.96 |
| PBDIT / Share (Rs.) | 15.49 | 17.13 | 12.97 | 14.45 | 12.30 |
| PBIT / Share (Rs.) | 12.69 | 14.61 | 11.18 | 12.78 | 10.63 |
| PBT / Share (Rs.) | 11.92 | 11.16 | 10.18 | 5.22 | 10.10 |
| Net Profit / Share (Rs.) | 8.57 | 7.79 | 7.37 | 2.23 | 7.17 |
| NP After MI And SOA / Share (Rs.) | 8.00 | 7.21 | 6.80 | 1.45 | 6.64 |
| PBDIT Margin (%) | 20.15 | 23.28 | 17.97 | 20.04 | 21.98 |
| PBIT Margin (%) | 16.51 | 19.86 | 15.49 | 17.72 | 18.99 |
| PBT Margin (%) | 15.51 | 15.17 | 14.11 | 7.24 | 18.03 |
| Net Profit Margin (%) | 11.14 | 10.59 | 10.20 | 3.09 | 12.81 |
| NP After MI And SOA Margin (%) | 10.41 | 9.79 | 9.42 | 2.01 | 11.86 |
| Return on Networth / Equity (%) | 8.02 | 7.80 | 8.01 | 1.83 | 8.47 |
| Return on Capital Employeed (%) | 11.84 | 14.51 | 12.08 | 15.13 | 12.55 |
| Return On Assets (%) | 6.48 | 6.21 | 6.12 | 1.35 | 6.36 |
| Long Term Debt / Equity (X) | 0.01 | 0.03 | 0.04 | 0.02 | 0.04 |
| Total Debt / Equity (X) | 0.06 | 0.09 | 0.11 | 0.12 | 0.12 |
| Asset Turnover Ratio (%) | 0.64 | 0.64 | 0.53 | 0.59 | 0.47 |
| Current Ratio (X) | 4.81 | 5.08 | 3.61 | 3.33 | 3.76 |
| Quick Ratio (X) | 4.08 | 4.34 | 3.08 | 2.80 | 3.27 |
| Inventory Turnover Ratio (X) | 6.63 | 3.06 | 2.96 | 3.71 | 2.73 |
| Dividend Payout Ratio (NP) (%) | 6.22 | 6.90 | 7.32 | 34.41 | 7.52 |
| Dividend Payout Ratio (CP) (%) | 4.61 | 5.11 | 5.79 | 15.98 | 6.01 |
| Earning Retention Ratio (%) | 93.78 | 93.10 | 92.68 | 65.59 | 92.48 |
| Cash Earning Retention Ratio (%) | 95.39 | 94.89 | 94.21 | 84.02 | 93.99 |
| Interest Coverage Ratio (X) | 20.10 | 25.95 | 13.04 | 31.60 | 23.01 |
| Interest Coverage Ratio (Post Tax) (X) | 12.12 | 17.03 | 8.40 | 21.40 | 14.42 |
| Enterprise Value (Cr.) | 1137.76 | 1087.33 | 770.70 | 752.99 | 990.81 |
| EV / Net Operating Revenue (X) | 1.41 | 1.41 | 1.03 | 1.01 | 1.72 |
| EV / EBITDA (X) | 6.97 | 6.06 | 5.70 | 5.03 | 7.81 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| Retention Ratios (%) | 93.77 | 93.09 | 92.67 | 65.58 | 92.47 |
| Price / BV (X) | 1.18 | 1.22 | 0.83 | 0.97 | 1.26 |
| Price / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| EarningsYield | 0.06 | 0.06 | 0.09 | 0.01 | 0.06 |
After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.23 (Mar 24) to 8.02, marking an increase of 0.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 7.11 (Mar 24) to 7.95, marking an increase of 0.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.36. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.36, marking an increase of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 76.85. It has increased from 73.57 (Mar 24) to 76.85, marking an increase of 3.28.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.49. This value is within the healthy range. It has decreased from 17.13 (Mar 24) to 15.49, marking a decrease of 1.64.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 12.69, marking a decrease of 1.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 11.16 (Mar 24) to 11.92, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 8.57, marking an increase of 0.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 8.00, marking an increase of 0.79.
- For PBDIT Margin (%), as of Mar 25, the value is 20.15. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 20.15, marking a decrease of 3.13.
- For PBIT Margin (%), as of Mar 25, the value is 16.51. This value is within the healthy range. It has decreased from 19.86 (Mar 24) to 16.51, marking a decrease of 3.35.
- For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 15.17 (Mar 24) to 15.51, marking an increase of 0.34.
- For Net Profit Margin (%), as of Mar 25, the value is 11.14. This value exceeds the healthy maximum of 10. It has increased from 10.59 (Mar 24) to 11.14, marking an increase of 0.55.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.41. This value is within the healthy range. It has increased from 9.79 (Mar 24) to 10.41, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.02. This value is below the healthy minimum of 15. It has increased from 7.80 (Mar 24) to 8.02, marking an increase of 0.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.84. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.84, marking a decrease of 2.67.
- For Return On Assets (%), as of Mar 25, the value is 6.48. This value is within the healthy range. It has increased from 6.21 (Mar 24) to 6.48, marking an increase of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. There is no change compared to the previous period (Mar 24) which recorded 0.64.
- For Current Ratio (X), as of Mar 25, the value is 4.81. This value exceeds the healthy maximum of 3. It has decreased from 5.08 (Mar 24) to 4.81, marking a decrease of 0.27.
- For Quick Ratio (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 2. It has decreased from 4.34 (Mar 24) to 4.08, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.63. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 6.63, marking an increase of 3.57.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.22. This value is below the healthy minimum of 20. It has decreased from 6.90 (Mar 24) to 6.22, marking a decrease of 0.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.61. This value is below the healthy minimum of 20. It has decreased from 5.11 (Mar 24) to 4.61, marking a decrease of 0.50.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.78. This value exceeds the healthy maximum of 70. It has increased from 93.10 (Mar 24) to 93.78, marking an increase of 0.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.39. This value exceeds the healthy maximum of 70. It has increased from 94.89 (Mar 24) to 95.39, marking an increase of 0.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.10. This value is within the healthy range. It has decreased from 25.95 (Mar 24) to 20.10, marking a decrease of 5.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has decreased from 17.03 (Mar 24) to 12.12, marking a decrease of 4.91.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,137.76. It has increased from 1,087.33 (Mar 24) to 1,137.76, marking an increase of 50.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.41.
- For EV / EBITDA (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 6.97, marking an increase of 0.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For Retention Ratios (%), as of Mar 25, the value is 93.77. This value exceeds the healthy maximum of 70. It has increased from 93.09 (Mar 24) to 93.77, marking an increase of 0.68.
- For Price / BV (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 1.18, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bliss GVS Pharma Ltd:
- Net Profit Margin: 11.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.84% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18 (Industry average Stock P/E: 54.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.14%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nandkumar K Chodankar | Chairman & Ind.Director |
| Mr. Gagan Harsh Sharma | Managing Director |
| Dr. Vibha Gagan Sharma | Whole Time Director |
| Mrs. Shruti Vishal Rao | Whole Time Director |
| Mr. Santosh L Parab | Independent Director |
| Ms. Shilpa Bhatia | Independent Woman Director |
FAQ
What is the intrinsic value of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's intrinsic value (as of 08 January 2026) is ₹129.16 which is 30.93% lower the current market price of ₹187.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,974 Cr. market cap, FY2025-2026 high/low of ₹196/105, reserves of ₹1,122 Cr, and liabilities of ₹1,400 Cr.
What is the Market Cap of Bliss GVS Pharma Ltd?
The Market Cap of Bliss GVS Pharma Ltd is 1,974 Cr..
What is the current Stock Price of Bliss GVS Pharma Ltd as on 08 January 2026?
The current stock price of Bliss GVS Pharma Ltd as on 08 January 2026 is ₹187.
What is the High / Low of Bliss GVS Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bliss GVS Pharma Ltd stocks is ₹196/105.
What is the Stock P/E of Bliss GVS Pharma Ltd?
The Stock P/E of Bliss GVS Pharma Ltd is 18.0.
What is the Book Value of Bliss GVS Pharma Ltd?
The Book Value of Bliss GVS Pharma Ltd is 107.
What is the Dividend Yield of Bliss GVS Pharma Ltd?
The Dividend Yield of Bliss GVS Pharma Ltd is 0.27 %.
What is the ROCE of Bliss GVS Pharma Ltd?
The ROCE of Bliss GVS Pharma Ltd is 11.7 %.
What is the ROE of Bliss GVS Pharma Ltd?
The ROE of Bliss GVS Pharma Ltd is 8.36 %.
What is the Face Value of Bliss GVS Pharma Ltd?
The Face Value of Bliss GVS Pharma Ltd is 1.00.